Introduction: Reduced vascular compliance in patients with hypertension results from an increase in extra-cellular matrix (ECM) protein deposition in blood vessels. At least two key factors, namely mechanical strain and neurohumoral mediators, for example Angiotensin II (Ang II), promote fibrogenesis within vessel walls; however potential interactions between these have not been clearly defined. This work examined the direct effect of mechanical strain on matrix mRNA expression and protein synthesis by human vascular smooth muscle (VSM) cells and identified the importance of reninangiotensin system (RAS) activation in stretch-induced matrix production. Methods: Human VSM cells were exposed either to a cyclical mechanical strain regimen or to Ang II in the presence or absence of the Ang II receptor (AT 1 R) antagonist losartan or its more potent metabolite EXP3174. Analysis of matrix mRNA expression (Northerns) and protein synthesis (ELISA) and cellular AT 1 -receptor protein expression (Westerns) were determined. Results: Ang II increased both collagen α1 (92%, SEM +/-20%) mRNA expression and fibronectin (21% +/-6%) protein synthesis in static VSM cells compared with unstimulated controls.The effect of Ang II was attenuated by antagonism of the AT 1 -receptor (AT 1 R). Similarly, mechanical strain induced an increase in both collagen α1 (102% +/-30%) mRNA expression and fibronectin (50% +/-21%) protein synthesis. Surprisingly, in the absence of exogenous Ang II, AT 1 -receptor blockade attenuated this stretch-induced increase in matrix synthesis. Mechanical strain also induced an increase in total cellular AT 1 -receptor protein (30.7% +/-3.5%) compared with static cells. Conclusion: Both mechanical strain and Ang II increased matrix gene expression and protein synthesis by human VSM cells. The effect of strain was attenuated by AT 1 -receptor antagonism. Our results further suggest that mechanical strain may sensitise human VSM cells to the fibrogenic actions of Ang II, perhaps via upregulation of the AT 1 -receptor.
Introduction
Chronic hypertension and increasing age lead to a reduction in blood vessel compliance as a consequence of increased extra-cellular matrix (ECM) protein deposition within the vessel wall. [1] [2] [3] These changes disturb the haemodynamic performance of large blood vessels, increase pulse wave velocity 4 and ultimately increase the risk of cardiovascular morbidity and mortality. 5 Vascular smooth muscle (VSM) cells are the predomi-nant source of deposited matrix proteins (Type I and III collagen, Fibronectin) 6, 7 and recent interest has focused on the factors regulating VSM cell protein synthesis and in particular their interaction at a cellular or molecular level. Vascular matrix deposition is induced by at least two major factors, namely neurohumoral mediators (i.e. Angiotensin II) and increased mechanical strain within the vascular wall of hypertensive patients. In human VSM cells, both Angiotensin II (Ang II) and strain independently increase matrix synthesis. [8] [9] [10] [11] [12] Presently it is unclear whether mechanical strain and Ang II act synergistically to accelerate matrix synthesis by VSM cells. [13] [14] [15] [16] [17] [18] [19] [20] Of particular importance, there have been no studies to date reporting the interaction between Ang II and mechanical strain in human VSM cells. This distinction is important because previous studies have generated species-dependent differences in matrix protein synthesis in response to mechanical strain. 21 There are a number of possibilities whereby strain and Ang II might interact to influence ECM protein synthesis by human VSM cells. First, mechanical strain may increase Ang II production by VSM cells. Secondly, strain may sensitise VSM cells to Ang II-induced ECM synthesis either by strain-induced upregulation of Ang II receptors and/or lead to post receptor co-operativity by acting via a common intracellular signalling pathway. In this paper we explore the role of the Renin-Angiotensin System (RAS) and Ang II in the regulation of ECM mRNA expression and protein synthesis by human VSM cells in response to in vitro chronic cyclical mechanical strain.
Methods
Human VSM cell culture VSM cells were obtained from human saphenous veins during surgical procedures as described earlier. 22 Ethics committee approval and consent had been given. Briefly, after removal of the endothelial layer by debridement, the VSM cell layer was diced into sections of less than 1 mm 3 . The cell suspension was suspended in media containing Ham's F12 medium (Sigma), 0.5% chick embryo extract (Gibco, Life Technology), 2 mmol/L L-glutamine, 100 units/ml penicillin and 100 µg/ml streptomycin supplemented with 20% fetal calf serum (FCS) (Gibco, Life Technologies) and cultured in humidified air at 37 o C with 5% CO 2 .The cell monolayers were passaged every 6-7 days using 0.1% trypsin. Human VSM cells from the second to the fourth passage, which had been serum-deprived for 48 hours, were used for experimentation.
Chronic cyclical mechanical strain
The Flexercell Stress Unit (Flexcell Corp, Pennsylvannia, USA) provides the equipment for the application of mechanical strain to cultured cells in vitro. Human VSM cells were seeded onto flexible elastomer culture wells coated with collagen I (Bioflex) and grown to 80-90% confluence as described above. The cells were serumdeprived for 48 hours prior to experimentation. During the experiment, the plates were incubated in 5% FCS and housed within a manifold and subjected to a computer-generated vacuum. The stretch:relaxation cycle (elongation 22%/16% at 1 Hz) to which the VSM cells were exposed was programmed into the computer, mimicking the percentage cell elongation and relaxation experienced by VSM cells in large vessels during the cardiac cycle in vivo. 23 
mRNA analysis
Total cellular RNA was prepared from cultured human VSM cells using the guanidium-phenol-chloroform purification method. 22 Following ethanol precipitation, RNA samples (20 µg/lane) were separated on a 1.2% agarose gel containing 6% formaldehyde and blotted onto Hybond-N membranes (Amersham Pharmacia). 20 ng cDNA probes for human collagen αI (Gift from Dr. J Norman, UCL) or human glyceraldehyde-30 phosphate dehydrogenase (GAPDH [no. 9805/1; Clontech]) were radiolabelled with 32 P dCTP (Amersham) using a commercial random priming labelling system (Gibco, Life Technologies). Hybridization took place overnight at 42 o C in 50% formamide, 5x SSPE, 5% Denhart's solution, 0.5% SDS, 6% (w/v) polyethylene glycol 6000 (Fisons) and salmon sperm DNA. Subsequently, blots were washed to high stringency (0.25x SSC, 0.15% SDS at 60 o C). The blots were exposed to Kodak XAR2 film with an intensifying screen at -70 o C for up to 48 hours. To standardise for mRNA expression, the blots were stripped and hybridized with GAPDH, a constantly expressed gene that is not influenced by Ang II or mechanical strain. The resulting autoradiographs were subjected to densitometric analysis using a Sharp JX-330 densitometer to quantify the mRNA ratio of collagen αI to GAPDH.
Fibronectin protein synthesis
Fibronectin concentrations in the cell media were measured with a specific enzyme linked immunosorbent assay. 1:1000 Rabbit anti-human fibronectin antibody (Sigma) in buffer (0.005 M Na 2 CO 3 , 0.045 M NaHCO 3 , pH 9.6) coated each well of a 96 well plate (Immuno plates -Maxisorp, Nunc F96) and kept at 4 o C overnight. Unbound primary antibody was removed by washing three times in washing buffer (WB) (PBS, 0.1% Tween) and these washing steps followed each incubation. Incubating each well in 2% bovine serum albumin in WB at room temperature eliminated non-specific binding sites. The samples were diluted 1:50 in WB and added to each well in duplicate. Serial concentrations of fibronectin (Sigma) were used to generate a standard curve. Following incubation of the samples the secondary antibody (1:500 mouse monoclonal antifibronectin antibody [Sigma]) was added. This was followed by addition of the enzyme conjugate -1:1000 Horse Radish Peroxidase conjugated rabbit anti-mouse IgG (Amersham). Finally, the plates were incubated with the substrate (citrate phosphate buffer solution (65mM Na 2 HPO 4 .12H 2 O, 35mM citric acid, H 2 O 2 and 8 mg Dako-OPD tablets).The reaction was terminated by the addition of 1M sulphuric acid and the protein content was quantified by reading at OD 492 using a Dynatech ELISA plate reader.
AT 1 -receptor protein expression
AT 1 -receptor protein expression was analysed from total cellular protein extracts. Cells were lysed in ice-cold homogenisation buffer (Tris-EDTA, Leupeptin [Sigma] 10 µg/ml; E64 [Sigma] 20 µM;Aprotinin 2 µg/ml; Pepstatin A [Sigma] 1 mm; Sodium fluoride 50 mM; Sodium orthovanadate 2.5 mM; β-glycerophosphate 62.5 mM; Triton X-100 0.1 %; Phenylmethylsulfonylflouride 1 mM; pH 7.4). The lysate was centrifuged to remove cells and a portion of the supernatant was added to 4x reducing buffer (0.125 M Tris pH 6.8; 20% Glycerol; 4% SDS; 0.2% Bromophenol blue) and boiled for 5 minutes prior to storage at -80 o C. The remaining supernatant was used for protein content analysis in duplicate following the Biorad Microassay Protocol. Equal amounts of samples were electrophoresed through a 10% Polyacrylamide / SDS gel and then transferred onto a Hybond-N membrane by Western blotting overnight. The blot was visualised with Ponceau S and then destained with 1x Phosphate Buffered Saline / 0.1% Tween-20 (PBS-T). The non-specific binding sites were blocked by the addition of 10% Marvel / 10% PBS-T (Antigenbioclear) prior to incubation with the primary antibody (1:500 rabbit polyclonal anti-human AT 1receptor). After several washes, the blot was incubated with 1:2000 anti-rabbit HRP antibody (Amersham). Finally, equal amounts of ECL reagents A and B (Amersham) were applied to the blot for one minute, drained off and the membrane was exposed to hyperfilm ECL (Amersham) for 1-20 minutes. The resulting autoradiographs were subjected to densitometric analysis using a Sharp JX-330 densitometer to quantify protein synthesis.
Materials
Angiotensin II was provided by Sigma. Merck & Co kindly donated the losartan and EXP 3174.
Statistics
The results are expressed as percentage increase mean ± SEM and statistics were analysed by the repeated measures ANOVA. Experiments were conducted at least in triplicate. For comparison, controls have standardised to an arbitrary value.
Results

Induction of ECM gene expression and protein synthesis in human VSM cells by angiotensin II
Collagen α1 mRNA and fibronectin protein levels were examined as indices of ECM mRNA expression and protein synthesis respectively. Ang II (10 -6 M) was added to human VSM cells with or without co-incubation of an AT 1 -receptor antagonist (losartan [10 -5 M] or its metabolite EXP 3174 [10 -5 M]) for up to 12 hours. Unstimulated cells served as controls. Ang II induced a 92% (SEM +/-20%) increase in collagen α1 mRNA at 3 hours, which was significantly attenuated by losartan (Figure 1a -p=0.04). Ang II also induced a 21% (+/-6%) increase in fibronectin protein synthesis at 12 hours, which was partially attenuated by losartan (+ 12% +/-5%) and abolished by EXP 3174 (-11% +/-3%) (Figure 1b -p=0 .05).
Effect of AT 1 -receptor antagonism on mechanical strain-induced matrix synthesis in human VSM cells
Chronic cyclical mechanical strain was applied to human VSM cells with or without co-incubation of an AT 1 -receptor antagonist (losartan [10 -5 M]) for up to 24 hours. No exogenous Ang II was added to the culture media. Static human VSM cells cultured on identical plates served as controls. Mechanical strain induced a 102% (+/-30%) increase in collagen α1 mRNA at 12 hours which was markedly and significantly attenuated by losartan to an increase of only 18% (+/-19%) (Figure 2a Journal of the Renin-
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Mechanical strain increases total human VSM cellular AT 1 -receptor protein
Chronic cyclical mechanical strain was applied to human VSM cells for 24 hours. Static human VSM cells cultured on identical plates served as controls. Mechanical strain induced a 30.7% (+/-3.5%) increase in total cellular AT 1 -receptor protein compared with static cells (Figure 3 -p=0 .01).
Discussion
Ang II and mechanical strain independently induce matrix synthesis at both the mRNA and protein levels in human VSM cells. Our study suggests that straininduced activation of the RAS is likely to be involved in this response, since mechanical strain-induced matrix synthesis is markedly attenuated by the AT 1 -receptor antagonist losartan. Previous studies in animals have suggested that mechanical strain may increase ECM protein production via an interaction with the RAS. Initially, Sadoshima proposed that strain induced release of Ang II from granules within rat neonatal cardiomyocytes. 14 Kojima provided further evidence in the same cell culture model by demonstrating attenuation of strain-induced cell signalling by AT 1 -receptor antagonism. 15 However, this and other studies 16 failed to identify an increase in Ang II concentrations in strain-conditioned media. Finally, Kijima proposed not only cellular activation of the RAS, but also an increase in AT 1 -receptors (but not receptor affinity) in neonatal cells. 17 Bardy 18 used an organ culture of rabbit aorta ex vivo and Li 19 cultured rabbit aortic VSM cells, which, to date, have been the models bearing most resemblance to adult human cells. Both studies revealed attenuation of stretch-induced matrix protein synthesis by AT 1 -receptor antagonism, but interestingly, the former identified an increase in cellular Ang II production. We have shown that AT 1 antagonism attenuates the effects of strain on human VSM cells. Furthermore, we have shown that strain induces AT 1 -receptor protein synthesis and have identified a greater than 200% increase in AT 1 mRNA after 3 hours of stretch (unpublished data). This evidence supports the hypothesis that strain sensitises VSM cells to the effects of Ang II by AT 1receptor upregulation and we are currently examining the impact of mechanical strain on AT 1 -receptor binding kinetics. This study was not designed to establish whether strain induces Ang II release from VSM cells. Although no exogenous Ang II was added to the culture media of stretched cells, Ang II is present in FCS and, even at very low concentrations, may elicit a physiological response without the need of cellular synthesis of Ang II. We speculate that the fibrogenic response to mechanical strain is enhanced via upregulation of the AT 1 -receptor which binds small quantities of Ang II in the culture media and increases the action of Ang II on fibrogenesis.
In conclusion, we have identified a Strain-Angiotensin II Multiplier System in human VSM cells that promotes fibrogenesis. Significantly, this highlights an augmentation in the response to Ang II rather than an increase in Ang II per se. Translating this into patients with hypertension, we can postulate that higher blood pressure may lead to an increased response to Ang II by the human vasculature by upregulating the AT 1 -receptor. This is potentially a very important concept because it implies that there is no increase in synthesis, but an increase in Ang II activity via receptor upregulation in vessels exposed to increased mechanical strain. Thus, inhibition of the AT 1 -receptor rather than inhibition of Ang II synthesis (ie by ACE inhibition) might be a more effective strategy to limit strain-induced vascular fibrosis if this mechanism is operative in vivo.
